ArticleCurrent drug targets2026
Research on the Anti-breast Hyperplasia Mechanism of Liqi Sanjie Granules Based on Network Pharmacological Analysis and Experimental Verification.
Article in Current drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast hyperplasia has become a major public health challenge due to changes in dietary patterns. However, there is still a lack of effective pharmacotherapy for Breast hyperplasia.
methodsThe chemical components of Liqi Sanjie Granules (LSG) were quantified through HPLC. Three key components were screened out by combining network pharmacology methods and experimental determination methods, whereas key components in sera were quantified through LC-MS. The potential molecular mechanisms of LSG and these three blood-entering chemicals for the treatment of breast hyperplasia were predicted by network pharmacology. Estradiol benzoate and progesterone were injected intramuscularly to establish a breast hyperplasia model. Serum estradiol (E2), progesterone (P), testosterone (T), and prolactin (PRT) were detected by ELISA. H&E was used in monitoring the hyperplasia of rat mammary gland tissues. Immunohistochemistry and RT-PCR were used to detect the protein and mRNA expression levels of estrogen receptors (ERs) and progesterone receptors (PR) in rat mammary glands.
resultsThe contents of seven components in LSG were quantified. After administration, the levels of paeoniflorin, glycyrrhizin, and ferulic acid were 280.16 ± 64.77, 101.87 ± 7.88, and 253.28 ± 17.64 μg per 200 μL, respectively. Network pharmacology studies have shown that LSG treats breast hyperplasia by acting on 63 targets in 36 signaling pathways, and the blood-entering chemicals of LSG involve 18 potential targets and 5 signaling pathways. Histopathological analysis revealed that rats in the LSG group had fewer mammary lobules and acini. Additionally, the proliferation of glandular epithelial cells was reduced. No significant changes were found in the serum levels of E2, P, PRT, and T in the LSG group. Concurrently, LSG can reduce the expression levels of PR protein and the mRNA of ESR1 and PGR in the rat mammary glands. DISCUSSION: This study suggests that the blood-entering chemicals paeoniflorin, glycyrrhizin, and ferulic acid may alleviate breast hyperplasia through decreasing the expression levels of ER, ESR1, and PGR in the mammary tissues, reducing the number of mammary lobules and alveoli, and inhibiting pathological changes in vacuolar degeneration, hyperplasia, and detachment of glandular epithelial cells.
conclusionsThis study quantitatively analysed the seven chemical components of LSG and determined the contents of paeoniflorin, glycyrrhizin, and ferulic acid in the medicated serum. Furthermore, it demonstrates that LSG improves breast hyperplasia by regulating ER and PR expression levels.
Indexed as
Identifiers
41879444What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.